Sutro Biopharma’s Option Grant Agreement with Vaxcyte

Martina Bellini
Tagged:

Fenwick represented Sutro Biopharma on the deal.Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), announced its option grant agreement…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

…

This content is for Standard 1 Year members only.
Login Join Now